EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Directed evolution of metalloproteinase inhibitor TIMP-1 for selective inhibition of MMP-9 exploits catalytic and fibronectin domain interactions

Alireza Shoari, Mathew A Coban, Alexandra Hockla, Arlinda Rezhdo, Alexandra M Dimesa, Maryam Raeeszadeh-Sarmazdeh, James A Van Deventer, Evette S Radisky

Journal of Biological Chemistry · 2025-06 · 301 (6) · 110258

DOI: 10.1016/j.jbc.2025.110258 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025-06. Verfasst von Alireza Shoari und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA. Hauptthemen laut MEDLINE: Tissue Inhibitor of Metalloproteinase-1, Matrix Metalloproteinase 9, Fibronectins, Matrix Metalloproteinase Inhibitors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Matrix metalloproteinase-9 (MMP-9) is a critical enzyme involved in extracellular matrix degradation and is strongly implicated in many diseases, including triple-negative breast cancer and other poor prognosis cancers. Selective inhibition of MMP-9 is therefore a promising therapeutic strategy. However, development of MMP inhibitors has been hindered by challenges in achieving specificity, with past efforts failing in clinical trials due to off-target effects and associated toxicity. Here, we present a novel approach to overcoming these challenges by engineering tissue inhibitor of metalloproteinases-1 (TIMP-1), a natural broad-spectrum MMP inhibitor, to achieve enhanced specificity and affinity for MMP-9. We demonstrate that TIMP-1 can be strategically engineered to selectively inhibit MMP-9 through modulating interactions not only with the catalytic domain but also with the unique fibronectin (FN) domains. By leveraging yeast surface display with strategic library design, we identified TIMP-1 variants that exploit multiple surface epitopes to optimize interactions with both the catalytic and FN domains of MMP-9. Molecular dynamics simulations further suggest how modifications in the N-terminal and C-terminal domains of TIMP-1 drive these selective interactions. The top engineered TIMP-1 variant exhibited significantly improved selectivity for MMP-9 in a manner dependent upon novel interactions with the FN domains, as validated through inhibition kinetics. This variant also demonstrated potent inhibition of MMP-9-driven triple-negative breast cancer cell invasiveness, underscoring the therapeutic potential of this approach. Our study highlights the versatility of TIMP-1 as a scaffold that can be optimized for highly selective MMP inhibition, providing new avenues for the development of targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tissue Inhibitor of Metalloproteinase-1Matrix Metalloproteinase 9FibronectinsMatrix Metalloproteinase InhibitorsDirected Molecular EvolutionHumansCatalytic DomainMolecular Dynamics SimulationTriple Negative Breast NeoplasmsCell Line, TumorProtein Domains

Stichwörter der Autor:innen

directed evolutionmatrix metalloproteinaseprotein engineeringtissue inhibitor of metalloproteinasesyeast surface display

Substanzen

Tissue Inhibitor of Metalloproteinase-1Matrix Metalloproteinase 9FibronectinsTIMP1 protein, humanMatrix Metalloproteinase InhibitorsMMP9 protein, human

Autor:innen und Institutionen

  • Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA.
  • Chemical and Biological Engineering Department, Tufts University, Medford, Massachusetts, USA.
  • Chemical and Materials Engineering, University of Nevada, Reno, Nevada, USA.
  • Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA. Electronic address: radisky.evette@mayo.edu.

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • NHLBI NIH HHS
  • National Heart Lung and Blood Institute
  • National Institutes of Health National Cancer Institute
  • Mayo Clinic
  • National Institutes of Health
  • United Nations Foundation

Zitieren

APA

Shoari, A., Coban, M. A., Hockla, A., Rezhdo, A., Dimesa, A. M., Raeeszadeh-Sarmazdeh, M., Van Deventer, J. A., & Radisky, E. S. (2025). Directed evolution of metalloproteinase inhibitor TIMP-1 for selective inhibition of MMP-9 exploits catalytic and fibronectin domain interactions. Journal of Biological Chemistry, 301(6), 110258. https://doi.org/10.1016/j.jbc.2025.110258

Vancouver

Shoari A, Coban MA, Hockla A, Rezhdo A, Dimesa AM, Raeeszadeh-Sarmazdeh M, et al. Directed evolution of metalloproteinase inhibitor TIMP-1 for selective inhibition of MMP-9 exploits catalytic and fibronectin domain interactions. Journal of Biological Chemistry. 2025;301(6):110258. doi:10.1016/j.jbc.2025.110258

BibTeX
@article{Shoari2025,
  author = {Shoari, Alireza and Coban, Mathew A and Hockla, Alexandra and Rezhdo, Arlinda and Dimesa, Alexandra M and Raeeszadeh-Sarmazdeh, Maryam and Van Deventer, James A and Radisky, Evette S},
  title = {Directed evolution of metalloproteinase inhibitor TIMP-1 for selective inhibition of MMP-9 exploits catalytic and fibronectin domain interactions},
  journal = {Journal of Biological Chemistry},
  year = {2025},
  volume = {301},
  number = {6},
  pages = {110258},
  doi = {10.1016/j.jbc.2025.110258}
}
Kostenlos starten →